Short‐ and long‐term outcomes of gestational diabetes and its treatment on fetal development
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Globally the prevalence of gestational diabetes mellitus (GDM) is rising mainly due to the increase in maternal obesity. A number of different methods to screen for and diagnose GDM have been described although consensus on the preferred methods does not yet exist. GDM has significant short‐ and long‐term health risks for the mother, developing fetus and the children born to mothers with GDM. Short‐term risks for the fetus include macrosomia (excessive birthweight), shoulder dystocia, birth trauma, and hypoglycaemia in the immediate postpartum period. Long‐term risks for offspring born to mothers with GDM include increased rates of childhood and adulthood obesity and an increased cardiometabolic risk. A number of pharmacological treatments for GDM have been identified, these include insulin and oral glucose‐lowering drugs metformin and glibenclamide. Whilst these oral glucose‐lowering drugs show similar short‐term childhood outcomes to insulin there is increasing evidence that these drugs may have adverse long‐term outcomes on children and adults exposed to the drugs in utero. Future research on treatments for GDM should include long‐term follow‐ up of children exposed to glucose lowering medication in utero to determine the long‐term cardiometabolic risk in the offspring born to mothers with GDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 1×
“admission to the NNU was 6% in the glibenclamide group vs 7% in the insulin group).(41) However, there is paucity of evidence regarding the long-term childhood outcomes of the use of glibenclamide”
BackgroundSacks, D. A., Hadden, D. R., Maresh, M., Deerochanawong, C., Dyer, A. R., Metzger, B. E., Lowe, L. P., Coustan, D. R., Hod, M., Oats, J. J. N., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1641 · Cited by 687
Macintosh, M. C. M., Fleming, K. M., Bailey, J. A., Doyle, P., Modder, J., Acolet, D., Golightly, S., & Miller, A. (2006) · BMJ · doi:10.1136/bmj.38856.692986.ae · Cited by 673
Wendland, E. M., Torloni, M. R., Falavigna, M., Trujillo, J., Dode, M. A., Campos, M. A., Duncan, B. B., & Schmidt, M. I. (2012) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-12-23 · Cited by 626
Damm, P., Houshmand-Oeregaard, A., Kelstrup, L., Lauenborg, J., Mathiesen, E. R., & Clausen, T. D. (2016) · Diabetologia · doi:10.1007/s00125-016-3985-5 · Cited by 620
Lowe, W. L., Scholtens, D. M., Lowe, L. P., Kuang, A., Nodzenski, M., Talbot, O., Catalano, P. M., Linder, B., Brickman, W. J., Clayton, P., et al. (2018) · JAMA · doi:10.1001/jama.2018.11628 · Cited by 591 · cited 12×
“Metformin crosses the placenta and has similar concentrations in fetal and maternal circulations and thus has the potential to affect the developing feto-placental unit.44 A large randomized controlled trial of metformin vs insulin for the treatment of GDM (MiG trial) showed no increased in short term adverse outcomes…”
BackgroundInfluentialTrying to understand gestational diabetes
Catalano, P. M. (2014) · Diabetic Medicine · doi:10.1111/dme.12381 · Cited by 456 · cited 2×
“Women with GDM have increased insulin resistance compared to women without GDM and this resistance is likely to be present prior to pregnancy and to persist across pregnancy.(11) The reduction in insulin sensitivity, combined with an inadequate response from the pancreatic beta cells”
BackgroundMetformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379
Insulin Action During Pregnancy: Studies with the Euglycemic Clamp Technique
Ryan, E. A., O'Sullivan, M. J., & Skyler, J. S. (1985) · Diabetes · doi:10.2337/diab.34.4.380 · Cited by 369
Feig, D. S., Hwee, J., Shah, B. R., Booth, G. L., Bierman, A. S., & Lipscombe, L. L. (2014) · Diabetes Care · doi:10.2337/dc13-2717 · Cited by 346
Scholtens, D. M., Kuang, A., Lowe, L. P., Hamilton, J., Lawrence, J. M., Lebenthal, Y., Brickman, W. J., Clayton, P., Ma, R. C., McCance, D., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2021 · Cited by 310
collaborators, O. B. O. T. A. D., O’Sullivan, E. P., Avalos, G., O’Reilly, M., Dennedy, M. C., Gaffney, G., & Dunne, F. (2011) · Diabetologia · doi:10.1007/s00125-011-2150-4 · Cited by 307
Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000456 · Cited by 305
Baz, B., Riveline, J.-P., & Gautier, J.-F. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0378 · Cited by 260
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002848 · Cited by 251 · cited 11×
“Metformin crosses the placenta and has similar concentrations in fetal and maternal circulations and thus has the potential to affect the developing feto-placental unit.44 A large randomized controlled trial of metformin vs insulin for the treatment of GDM (MiG trial) showed no increased in short term adverse outcomes…”
MethodInfluentialSchwartz, N., Nachum, Z., & Green, M. S. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.03.011 · Cited by 229
Hanem, L. G. E., Salvesen, Ø., Juliusson, P. B., Carlsen, S. M., Nossum, M. C. F., Vaage, M. Ø., Ødegård, R., & Vanky, E. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30385-7 · Cited by 134
SMFM statement: pharmacological treatment of gestational diabetes
(2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.041 · Cited by 94
Glyburide transport across the human placenta
Schwartz, R. A., Rosenn, B., Aleksa, K., & Koren, G. (2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000672 · Cited by 83 · cited 1×
“Transplacental transfer is highly variable, but concentrations in new borns are usually very low.(40) It has been shown in a large random-”
BackgroundDifferent methods and settings for glucose monitoring for gestational diabetes during pregnancy
Raman, P., Shepherd, E., Dowswell, T., Middleton, P., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011069.pub2 · Cited by 62
Insulin Use in Pregnancy: An Update
Blum, A. K. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.2.92 · Cited by 59 · cited 2×
“Insulin has been used safely in pregnancy for many years as it does not cross the placenta and the FDA has sufficient evidence to classify the risk of insulin use as “low” in pregnancy.(37) A Cochrane review reported limited evidence to support one type of insulin regimen over another(38) however there is growing evid…”
BackgroundRush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Rowan, J. (2015) · Annals of Human Biology · doi:10.3109/03014460.2014.959999 · Cited by 13
Research works printed but not linked: 18
- 10.1111/1471-0528.14236 · DOI · Paper page
- Diabetes Canada Clinial Practice Guidelines Expert Committee 2018, 2018, 2018 clinical practice guidelines for the prevention and management of diabetes in Canada, Can J Diabetes, 42, S1
- 10.1007/s00125-017-4206-6 · DOI · Paper page
- 10.2147/IJWH.S102117 · DOI
- 10.2337/diacare.27.2007.S88 · DOI · Paper page
- Brown J, 2016, Dietary supplementation with myo‐inositol in women during pregnancy for treating gestational diabetes, Cochrane Database System Rev., 9, CD012048
- 10.1007/s00404-017-4505-7 · DOI
- 10.1002/14651858.CD001997 · DOI
- 10.1111/j.1464-5491.2010.02978.x · DOI · Paper page
- 10.1210/jc.2013-1536 · DOI
- 10.1371/journal.pone.0036727 · DOI · Paper page
- The International Classification of Diseases 10th Edition (ICD‐10) changeover is coming. Optometry (St Louis Mo). 2010;81(10):551‐3. · doi:10.1016/j.optm.2010.07.020
- 10.1210/jc.2018-02743 · DOI
- O'Neill SM, 2017, Different insulin types and regimens for pregnant women with pre‐existing diabetes, Cochrane Database Systemat Rev., 2, CD011880
- 10.7573/dic.212282 · DOI · Paper page
- 10.1186/s12884-017-1505-3 · DOI
- 10.1097/01.ftd.0000184161.52573.0e · DOI · Paper page
- 10.1186/s12887-015-0372-1 · DOI
Cited by
Zang, L., Liu, X., Xie, X., Zhou, X., Pan, Y., & Dai, J. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.121504 · Cited by 42
Xie, W., Zhang, L., Cheng, J., Wang, Y., Kang, H., & Gao, Y. (2024) · BMC Public Health · doi:10.1186/s12889-024-18131-7 · Cited by 41
“…of both the mother and infant is adversely affected by GDM: pregnant women with GDM have a greater risk of obesity and hypertension in the short term, while the long-term risks for offspring born to mothers with GDM include an increased risk of developing type 2 diabetes mellitus (T2DM) [5, 6].”
BackgroundLiu, W., Gao, M., Yang, S., Sun, C., Bi, Y., Li, Y., Wang, J., & Yuan, X. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108451 · Cited by 26
Benton, M., Payne, E., Waheed, N., Turner, K., Murphy, H. R., Skouteris, H., Ismail, K., & Silverio, S. A. (2025) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70038
Metadata
- Authors
- Murray, S. R., & Reynolds, R. M.
- Venue
- Prenatal Diagnosis
- Publisher
- Wiley
- Published
- 2020-07
- Volume
- 40
- Issue
- 9
- Pages
- 1085-1091
- ISSN
- 0197-3851 (ISSN-L)
- 1097-0223
- OpenAlex
- W3036040816
- Cited by
- 104
- References
- 29
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.